abrocitinib vs upadacitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1 · full Atopic Dermatitis pipeline

abrocitinib · Cibinqo

Marketed by Pfizer

Approved in Atopic Dermatitissmall molecule
Reliable signal

NCT03349060 · Phase 3 · completed

A randomized, quadruple-blind, placebo-controlled phase 3 trial enrolling 387 participants with moderate-to-severe atopic dermatitis. The co-primary endpoints (IGA response and EASI-75 at week 12) were both statistically significant for the 100 mg and 200 mg doses versus placebo, with large absolute differences (e.g. 43.8% vs 7.9% for IGA). The adequate sample size, blinded design, and positive hard clinical endpoints justify the strong evidence grade.

Next expected readout: May 2027 · NCT07848074 (registry estimate)

Reported efficacy

Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2; Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4: Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2 (Week 2): Abrocitinib 200 mg QD 48.2% (95% CI 43 to 53.4) vs Dupilumab 300 mg Q2W 25.5% (95% CI 21.1 to 30) (met)

Result source: NCT04345367

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Atopic DermatitisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT03607422 · Phase 3 · completed

Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)

Result source: NCT03607422

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointabrocitinibupadacitinib
EASI-7539.7% vs 11.8%+27.9 vs placebo100 mg · wk 12 · n 156NCT03349060
94 other results
  • 44.5% vs 10.4% 100 mg · wk 12 · n 155 · Phase 3 · primary NCT03575871
  • 58.7% vs 27.1% 100 mg · wk 12 · n 235 · Phase 3 · primary NCT03720470
  • 68.5% vs 41.5% 100mg QD · wk 12 · n 89 · Phase 3 · primary NCT03796676
  • 62.7% vs 11.8% 200 mg · wk 12 · n 153 · Phase 3 · primary NCT03349060
  • 61% vs 10.4% 200 mg · wk 12 · n 154 · Phase 3 · primary NCT03575871
  • 70.3% vs 27.1% 200 mg · wk 12 · n 219 · Phase 3 · primary NCT03720470
  • 72% vs 41.5% 200mg QD · wk 12 · n 93 · Phase 3 · primary NCT03796676
  • 46.5% vs 14% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 54.2% vs 15.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 60.4% vs 18% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 60.3% vs 30.6% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 76% vs 27% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 100% vs 99.2% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 38.3% vs 13.3% 100 mg · wk 8 · n 155 · Phase 3 · secondary NCT03349060
  • 43.3% vs 12.8% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 55.6% vs 18.6% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 60.4% vs 33.3% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 27.6% vs 14.5% 100 mg · wk 4 · n 155 · Phase 3 · secondary NCT03349060
  • 26.5% vs 6.5% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 44.6% vs 15.6% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 41.3% vs 14.6% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 10.3% vs 3.9% 100 mg · wk 2 · n 155 · Phase 3 · secondary NCT03349060
  • 10.2% vs 1.3% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 25.4% vs 10.9% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 19.6% vs 4.4% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 65.8% vs 14% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 71.8% vs 15.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 80.5% vs 18% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 71% vs 30.6% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 92.5% vs 27% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 99.6% vs 99.2% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 57.8% vs 13.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 60.4% vs 12.8% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 67.9% vs 18.6% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 68.5% vs 33.3% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 47.4% vs 14.5% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 51% vs 6.5% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 57.4% vs 15.6% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 63.8% vs 14.6% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 24% vs 3.9% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 24.3% vs 1.3% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 30% vs 10.9% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 25.5% vs 4.4% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 73% vs 72.3% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 76.1% vs 71.1% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 77.3% vs 67.8% 200 mg QD · wk 16 · n 362 · Phase 3 · secondary NCT04345367
  • 76.3% vs 61.4% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 71% vs 52.8% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 57.6% vs 36.8% 200 mg QD · wk 4 · n 362 · Phase 3 · secondary NCT04345367
  • 29.4% vs 21.3% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 25% vs 32.1% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 35% vs 31.3% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 26.7% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 40.7% vs 15.4% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 40% vs 20% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 38.2% vs 16.4% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 27.3% vs 10.9% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 5.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.7% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 32.1% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 45.5% vs 31.3% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 55.6% vs 26.7% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 64.6% vs 15.4% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 73.6% vs 20% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 68.5% vs 16.4% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 57.4% vs 10.9% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 36.5% vs 5.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 16.7% vs 3.7% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 32.1% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 6.9% vs 31.3% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 26.7% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 13.3% vs 15.4% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 22% vs 20% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 18% vs 16.4% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 20% vs 10.9% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 5.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.7% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 38.5% vs 32.1% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 25% vs 31.3% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 27.6% vs 26.7% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 17.4% vs 15.4% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 22.4% vs 20% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 16.4% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.9% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 3.7% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 43.8% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 6.3% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 38.5% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
IGA 0/1 with 2-point improvement27.8% vs 6.3%+21.5 vs placebo100mg QD · wk 12 · n 56NCT02780167
35 other results
  • 44.5% vs 6.3% 200mg QD · wk 12 · n 55 · Phase 2 · primary NCT02780167
  • 12.3% vs 6.3% 30mg QD · wk 12 · n 51 · Phase 2 · primary NCT02780167
  • 8.2% vs 6.3% 10mg QD · wk 12 · n 49 · Phase 2 · primary NCT02780167
  • 13.9% vs 10.7% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 12.5% vs 18.8% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 14.5% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.6% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 1.8% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.7% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 15.9% vs 18.8% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 26.7% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 41.5% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 14.5% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 11.5% vs 3.6% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 10.7% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 3.4% vs 18.8% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 12% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 14.5% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.6% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 2% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 10.7% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 10.7% vs 18.8% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 20.7% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 14.5% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 3.6% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
—Trial running · NCT03568318
EASI-9028.5% vs 14.6%vs Dupilumab200 mg QD · wk 4 · n 354NCT04345367
94 other results
  • 38% vs 11.3% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 51.3% vs 13.9% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 18.6% vs 5.3% 100 mg · wk 12 · n 156 · Phase 3 · secondary NCT03349060
  • 23.9% vs 3.9% 100 mg · wk 12 · n 158 · Phase 3 · secondary NCT03575871
  • 36.6% vs 10.1% 100 mg · wk 12 · n 238 · Phase 3 · secondary NCT03720470
  • 41.6% vs 18.1% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • 87.1% vs 84.6% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 14.3% vs 5.3% 100 mg · wk 8 · n 156 · Phase 3 · secondary NCT03349060
  • 17.2% vs 2.6% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 30.6% vs 7.8% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 29.7% vs 14% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 7.9% vs 3.9% 100 mg · wk 4 · n 156 · Phase 3 · secondary NCT03349060
  • 9.7% vs 0% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 20.2% vs 6.3% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 17.4% vs 2.1% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 46.9% vs 10.5% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 1.9% vs 1.3% 100 mg · wk 2 · n 156 · Phase 3 · secondary NCT03349060
  • 2.5% vs 0% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 8.3% vs 2.3% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 8.7% vs 0% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 41.5% vs 12.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 37.6% vs 10.6% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 48.9% vs 11.3% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 77.1% vs 13.9% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 38.6% vs 5.3% 200 mg · wk 12 · n 154 · Phase 3 · secondary NCT03349060
  • 37.7% vs 3.9% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • 46.1% vs 10.1% 200 mg · wk 12 · n 226 · Phase 3 · secondary NCT03720470
  • 49.5% vs 18.1% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • 86.4% vs 84.6% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 33.1% vs 5.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 34.4% vs 2.6% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 47.3% vs 7.8% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 40.2% vs 14% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 24.3% vs 3.9% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 22.9% vs 0% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 32.3% vs 6.3% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 30.9% vs 2.1% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 64.5% vs 10.5% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 5.2% vs 1.3% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 9.2% vs 0% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 11.2% vs 2.3% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 10.6% vs 0% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 58.7% vs 12.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 54.5% vs 10.6% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 54.3% vs 41.9% 200 mg QD · wk 16 · n 357 · Phase 3 · secondary NCT04345367
  • 47.6% vs 33.6% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 58.4% vs 45.7% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 45.4% vs 25.4% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 54.6% vs 47.6% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 11.6% vs 7.2% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 8.3% vs 14.3% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 17.5% vs 15.6% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 25.9% vs 9.6% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 23.6% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 7.3% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 10.9% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 5.5% vs 0% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 0% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 10.5% vs 14.3% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 18.2% vs 15.6% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 31.1% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 52.1% vs 9.6% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 43.4% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 44.4% vs 7.3% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 38.9% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 19.2% vs 0% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 14.3% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 15.6% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 3.2% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 9.6% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 7.3% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 14.3% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 15.6% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 13.8% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 10.9% vs 9.6% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 7.3% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 0% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 37.5% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 57.1% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 28.6% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
EASI, % change-60% vs -28.6%−31.4 vs placebo100 mg · wk 12 · n 158NCT03575871
51 other results
  • -77.3% vs -63.7% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • -59.5% vs -33% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • -72.6% vs -57.6% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • -54.3% vs -24.4% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • -66.1% vs -41.7% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • -39.2% vs -9% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • -51.5% vs -27.6% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • -73.3% vs -28.6% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • -80.6% vs -63.7% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • -73.2% vs -33% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • -77.8% vs -57.6% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • -69% vs -24.4% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • -74.3% vs -41.7% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • -51.3% vs -9% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • -54.5% vs -27.6% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • -27.7% vs -35.9% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • -38.8% vs -35.5% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • -51.2% vs -29.8% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • -59.0% vs -35.2% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • -54.0% vs -36.7% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • -54.2% vs -39.2% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • -53.6% vs -24.6% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • -38.3% vs -23.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • -19.9% vs -12.3% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • -55.8% vs -35.9% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • -57.1% vs -35.5% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • -66.3% vs -29.8% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • -82.6% vs -35.2% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • -84.5% vs -36.7% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • -83.1% vs -39.2% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • -78.2% vs -24.6% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • -63.3% vs -23.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • -41.3% vs -12.3% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • -20.8% vs -35.9% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -35.5% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • -33.0% vs -29.8% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • -40.7% vs -35.2% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • -36.8% vs -36.7% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • -40.2% vs -39.2% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • -32.8% vs -24.6% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -23.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • -14.8% vs -12.3% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • -45.2% vs -35.9% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • -31.5% vs -35.5% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • -34.1% vs -29.8% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • -31.1% vs -35.2% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • -39.4% vs -36.7% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • -35.2% vs -39.2% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • -30.1% vs -24.6% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • -14.8% vs -23.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • -13.8% vs -12.3% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117

EASI-75

abrocitinib
39.7% vs 11.8%+27.9 vs placebo100 mg · wk 12 · n 156NCT03349060
94 other results
  • 44.5% vs 10.4% 100 mg · wk 12 · n 155 · Phase 3 · primary NCT03575871
  • 58.7% vs 27.1% 100 mg · wk 12 · n 235 · Phase 3 · primary NCT03720470
  • 68.5% vs 41.5% 100mg QD · wk 12 · n 89 · Phase 3 · primary NCT03796676
  • 62.7% vs 11.8% 200 mg · wk 12 · n 153 · Phase 3 · primary NCT03349060
  • 61% vs 10.4% 200 mg · wk 12 · n 154 · Phase 3 · primary NCT03575871
  • 70.3% vs 27.1% 200 mg · wk 12 · n 219 · Phase 3 · primary NCT03720470
  • 72% vs 41.5% 200mg QD · wk 12 · n 93 · Phase 3 · primary NCT03796676
  • 46.5% vs 14% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 54.2% vs 15.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 60.4% vs 18% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 60.3% vs 30.6% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 76% vs 27% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 100% vs 99.2% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 38.3% vs 13.3% 100 mg · wk 8 · n 155 · Phase 3 · secondary NCT03349060
  • 43.3% vs 12.8% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 55.6% vs 18.6% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 60.4% vs 33.3% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 27.6% vs 14.5% 100 mg · wk 4 · n 155 · Phase 3 · secondary NCT03349060
  • 26.5% vs 6.5% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 44.6% vs 15.6% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 41.3% vs 14.6% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 10.3% vs 3.9% 100 mg · wk 2 · n 155 · Phase 3 · secondary NCT03349060
  • 10.2% vs 1.3% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 25.4% vs 10.9% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 19.6% vs 4.4% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 65.8% vs 14% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 71.8% vs 15.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 80.5% vs 18% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 71% vs 30.6% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 92.5% vs 27% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 99.6% vs 99.2% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 57.8% vs 13.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 60.4% vs 12.8% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 67.9% vs 18.6% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 68.5% vs 33.3% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 47.4% vs 14.5% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 51% vs 6.5% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 57.4% vs 15.6% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 63.8% vs 14.6% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 24% vs 3.9% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 24.3% vs 1.3% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 30% vs 10.9% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 25.5% vs 4.4% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 73% vs 72.3% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 76.1% vs 71.1% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 77.3% vs 67.8% 200 mg QD · wk 16 · n 362 · Phase 3 · secondary NCT04345367
  • 76.3% vs 61.4% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 71% vs 52.8% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 57.6% vs 36.8% 200 mg QD · wk 4 · n 362 · Phase 3 · secondary NCT04345367
  • 29.4% vs 21.3% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 25% vs 32.1% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 35% vs 31.3% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 26.7% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 40.7% vs 15.4% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 40% vs 20% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 38.2% vs 16.4% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 27.3% vs 10.9% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 5.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.7% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 36.8% vs 32.1% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 45.5% vs 31.3% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 55.6% vs 26.7% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 64.6% vs 15.4% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 73.6% vs 20% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 68.5% vs 16.4% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 57.4% vs 10.9% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 36.5% vs 5.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 16.7% vs 3.7% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 32.1% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 6.9% vs 31.3% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 26.7% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 13.3% vs 15.4% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 22% vs 20% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 18% vs 16.4% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 20% vs 10.9% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 5.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.7% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 38.5% vs 32.1% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 25% vs 31.3% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 27.6% vs 26.7% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 17.4% vs 15.4% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 22.4% vs 20% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 16.4% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.9% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 3.7% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 43.8% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 46.7% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 6.3% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 78.6% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 38.5% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
upadacitinib
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117

IGA 0/1 with 2-point improvement

abrocitinib
27.8% vs 6.3%+21.5 vs placebo100mg QD · wk 12 · n 56NCT02780167
35 other results
  • 44.5% vs 6.3% 200mg QD · wk 12 · n 55 · Phase 2 · primary NCT02780167
  • 12.3% vs 6.3% 30mg QD · wk 12 · n 51 · Phase 2 · primary NCT02780167
  • 8.2% vs 6.3% 10mg QD · wk 12 · n 49 · Phase 2 · primary NCT02780167
  • 13.9% vs 10.7% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 12.5% vs 18.8% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 12.7% vs 14.5% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 3.6% vs 3.6% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 1.8% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 18.4% vs 10.7% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 15.9% vs 18.8% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 26.7% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 41.5% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 14.5% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 40.7% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 11.5% vs 3.6% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 10.7% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 3.4% vs 18.8% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 12.9% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 12% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 14.5% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 6% vs 3.6% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 2% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 10.7% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 10.7% vs 18.8% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 20.7% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 14.5% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 3.6% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
upadacitinib
—Trial running · NCT03568318

EASI-90

abrocitinib
28.5% vs 14.6%vs Dupilumab200 mg QD · wk 4 · n 354NCT04345367
94 other results
  • 38% vs 11.3% 100 mg · wk 16 · n 238 · Phase 3 · secondary NCT03720470
  • 51.3% vs 13.9% 100 mg · wk 16 · n 264 · Phase 3 · secondary NCT03627767
  • 18.6% vs 5.3% 100 mg · wk 12 · n 156 · Phase 3 · secondary NCT03349060
  • 23.9% vs 3.9% 100 mg · wk 12 · n 158 · Phase 3 · secondary NCT03575871
  • 36.6% vs 10.1% 100 mg · wk 12 · n 238 · Phase 3 · secondary NCT03720470
  • 41.6% vs 18.1% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • 87.1% vs 84.6% 100 mg · wk 12 · n 264 · Phase 3 · secondary NCT03627767
  • 14.3% vs 5.3% 100 mg · wk 8 · n 156 · Phase 3 · secondary NCT03349060
  • 17.2% vs 2.6% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • 30.6% vs 7.8% 100 mg · wk 8 · n 238 · Phase 3 · secondary NCT03720470
  • 29.7% vs 14% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • 7.9% vs 3.9% 100 mg · wk 4 · n 156 · Phase 3 · secondary NCT03349060
  • 9.7% vs 0% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • 20.2% vs 6.3% 100 mg · wk 4 · n 238 · Phase 3 · secondary NCT03720470
  • 17.4% vs 2.1% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • 46.9% vs 10.5% 100 mg · wk 28 · n 264 · Phase 3 · secondary NCT03627767
  • 1.9% vs 1.3% 100 mg · wk 2 · n 156 · Phase 3 · secondary NCT03349060
  • 2.5% vs 0% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • 8.3% vs 2.3% 100 mg · wk 2 · n 238 · Phase 3 · secondary NCT03720470
  • 8.7% vs 0% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • 41.5% vs 12.1% 100 mg · wk 40 · n 264 · Phase 3 · secondary NCT03627767
  • 37.6% vs 10.6% 100 mg · wk 52 · n 264 · Phase 3 · secondary NCT03627767
  • 48.9% vs 11.3% 200 mg · wk 16 · n 226 · Phase 3 · secondary NCT03720470
  • 77.1% vs 13.9% 200 mg · wk 16 · n 266 · Phase 3 · secondary NCT03627767
  • 38.6% vs 5.3% 200 mg · wk 12 · n 154 · Phase 3 · secondary NCT03349060
  • 37.7% vs 3.9% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • 46.1% vs 10.1% 200 mg · wk 12 · n 226 · Phase 3 · secondary NCT03720470
  • 49.5% vs 18.1% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • 86.4% vs 84.6% 200 mg · wk 12 · n 266 · Phase 3 · secondary NCT03627767
  • 33.1% vs 5.3% 200 mg · wk 8 · n 154 · Phase 3 · secondary NCT03349060
  • 34.4% vs 2.6% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • 47.3% vs 7.8% 200 mg · wk 8 · n 226 · Phase 3 · secondary NCT03720470
  • 40.2% vs 14% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • 24.3% vs 3.9% 200 mg · wk 4 · n 154 · Phase 3 · secondary NCT03349060
  • 22.9% vs 0% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • 32.3% vs 6.3% 200 mg · wk 4 · n 226 · Phase 3 · secondary NCT03720470
  • 30.9% vs 2.1% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • 64.5% vs 10.5% 200 mg · wk 28 · n 266 · Phase 3 · secondary NCT03627767
  • 5.2% vs 1.3% 200 mg · wk 2 · n 154 · Phase 3 · secondary NCT03349060
  • 9.2% vs 0% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • 11.2% vs 2.3% 200 mg · wk 2 · n 226 · Phase 3 · secondary NCT03720470
  • 10.6% vs 0% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • 58.7% vs 12.1% 200 mg · wk 40 · n 266 · Phase 3 · secondary NCT03627767
  • 54.5% vs 10.6% 200 mg · wk 52 · n 266 · Phase 3 · secondary NCT03627767
  • 54.3% vs 41.9% 200 mg QD · wk 16 · n 357 · Phase 3 · secondary NCT04345367
  • 47.6% vs 33.6% 200 mg QD · wk 12 · n 362 · Phase 3 · secondary NCT04345367
  • 58.4% vs 45.7% 200 mg QD · wk 20 · n 362 · Phase 3 · secondary NCT04345367
  • 45.4% vs 25.4% 200 mg QD · wk 8 · n 362 · Phase 3 · secondary NCT04345367
  • 54.6% vs 47.6% 200 mg QD · wk 26 · n 362 · Phase 3 · secondary NCT04345367
  • 11.6% vs 7.2% 200 mg QD · wk 2 · n 362 · Phase 3 · secondary NCT04345367
  • 8.3% vs 14.3% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • 17.5% vs 15.6% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • 23.7% vs 10% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • 25.9% vs 9.6% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • 23.6% vs 5.5% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • 16.4% vs 7.3% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • 10.9% vs 1.8% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • 5.5% vs 0% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • 0% vs 0% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • 10.5% vs 14.3% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • 18.2% vs 15.6% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • 31.1% vs 10% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • 52.1% vs 9.6% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • 43.4% vs 5.5% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • 44.4% vs 7.3% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • 38.9% vs 1.8% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • 19.2% vs 0% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • 7.4% vs 0% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • 3.7% vs 14.3% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 15.6% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • 3.2% vs 10% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • 0% vs 9.6% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 5.5% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • 14% vs 7.3% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • 8% vs 1.8% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • 4% vs 0% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • 23.1% vs 14.3% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 15.6% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • 13.8% vs 10% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • 10.9% vs 9.6% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • 12.2% vs 5.5% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • 14.3% vs 7.3% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • 8.2% vs 1.8% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • 6.1% vs 0% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • 2.1% vs 0% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
  • 37.5% vs 0% 100 mg QD · wk 12 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 8 · n 16 · Phase 2 · secondary NCT03915496
  • 20% vs 0% 100 mg QD · wk 4 · n 16 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 100 mg QD · wk 2 · n 16 · Phase 2 · secondary NCT03915496
  • 50% vs 0% 200 mg QD · wk 12 · n 14 · Phase 2 · secondary NCT03915496
  • 57.1% vs 0% 200 mg QD · wk 8 · n 14 · Phase 2 · secondary NCT03915496
  • 28.6% vs 0% 200 mg QD · wk 4 · n 14 · Phase 2 · secondary NCT03915496
  • 0% vs 0% 200 mg QD · wk 2 · n 14 · Phase 2 · secondary NCT03915496
upadacitinib
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117

EASI, % change

abrocitinib
-60% vs -28.6%−31.4 vs placebo100 mg · wk 12 · n 158NCT03575871
51 other results
  • -77.3% vs -63.7% 100mg QD · wk 12 · n 92 · Phase 3 · secondary NCT03796676
  • -59.5% vs -33% 100 mg · wk 8 · n 158 · Phase 3 · secondary NCT03575871
  • -72.6% vs -57.6% 100mg QD · wk 8 · n 92 · Phase 3 · secondary NCT03796676
  • -54.3% vs -24.4% 100 mg · wk 4 · n 158 · Phase 3 · secondary NCT03575871
  • -66.1% vs -41.7% 100mg QD · wk 4 · n 92 · Phase 3 · secondary NCT03796676
  • -39.2% vs -9% 100 mg · wk 2 · n 158 · Phase 3 · secondary NCT03575871
  • -51.5% vs -27.6% 100mg QD · wk 2 · n 92 · Phase 3 · secondary NCT03796676
  • -73.3% vs -28.6% 200 mg · wk 12 · n 155 · Phase 3 · secondary NCT03575871
  • -80.6% vs -63.7% 200mg QD · wk 12 · n 94 · Phase 3 · secondary NCT03796676
  • -73.2% vs -33% 200 mg · wk 8 · n 155 · Phase 3 · secondary NCT03575871
  • -77.8% vs -57.6% 200mg QD · wk 8 · n 94 · Phase 3 · secondary NCT03796676
  • -69% vs -24.4% 200 mg · wk 4 · n 155 · Phase 3 · secondary NCT03575871
  • -74.3% vs -41.7% 200mg QD · wk 4 · n 94 · Phase 3 · secondary NCT03796676
  • -51.3% vs -9% 200 mg · wk 2 · n 155 · Phase 3 · secondary NCT03575871
  • -54.5% vs -27.6% 200mg QD · wk 2 · n 94 · Phase 3 · secondary NCT03796676
  • -27.7% vs -35.9% 100mg QD · wk 16 · n 56 · Phase 2 · secondary NCT02780167
  • -38.8% vs -35.5% 100mg QD · wk 14 · n 56 · Phase 2 · secondary NCT02780167
  • -51.2% vs -29.8% 100mg QD · wk 13 · n 56 · Phase 2 · secondary NCT02780167
  • -59.0% vs -35.2% 100mg QD · wk 12 · n 56 · Phase 2 · secondary NCT02780167
  • -54.0% vs -36.7% 100mg QD · wk 8 · n 56 · Phase 2 · secondary NCT02780167
  • -54.2% vs -39.2% 100mg QD · wk 6 · n 56 · Phase 2 · secondary NCT02780167
  • -53.6% vs -24.6% 100mg QD · wk 4 · n 56 · Phase 2 · secondary NCT02780167
  • -38.3% vs -23.5% 100mg QD · wk 2 · n 56 · Phase 2 · secondary NCT02780167
  • -19.9% vs -12.3% 100mg QD · wk 1 · n 56 · Phase 2 · secondary NCT02780167
  • -55.8% vs -35.9% 200mg QD · wk 16 · n 55 · Phase 2 · secondary NCT02780167
  • -57.1% vs -35.5% 200mg QD · wk 14 · n 55 · Phase 2 · secondary NCT02780167
  • -66.3% vs -29.8% 200mg QD · wk 13 · n 55 · Phase 2 · secondary NCT02780167
  • -82.6% vs -35.2% 200mg QD · wk 12 · n 55 · Phase 2 · secondary NCT02780167
  • -84.5% vs -36.7% 200mg QD · wk 8 · n 55 · Phase 2 · secondary NCT02780167
  • -83.1% vs -39.2% 200mg QD · wk 6 · n 55 · Phase 2 · secondary NCT02780167
  • -78.2% vs -24.6% 200mg QD · wk 4 · n 55 · Phase 2 · secondary NCT02780167
  • -63.3% vs -23.5% 200mg QD · wk 2 · n 55 · Phase 2 · secondary NCT02780167
  • -41.3% vs -12.3% 200mg QD · wk 1 · n 55 · Phase 2 · secondary NCT02780167
  • -20.8% vs -35.9% 30mg QD · wk 16 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -35.5% 30mg QD · wk 14 · n 51 · Phase 2 · secondary NCT02780167
  • -33.0% vs -29.8% 30mg QD · wk 13 · n 51 · Phase 2 · secondary NCT02780167
  • -40.7% vs -35.2% 30mg QD · wk 12 · n 51 · Phase 2 · secondary NCT02780167
  • -36.8% vs -36.7% 30mg QD · wk 8 · n 51 · Phase 2 · secondary NCT02780167
  • -40.2% vs -39.2% 30mg QD · wk 6 · n 51 · Phase 2 · secondary NCT02780167
  • -32.8% vs -24.6% 30mg QD · wk 4 · n 51 · Phase 2 · secondary NCT02780167
  • -26.3% vs -23.5% 30mg QD · wk 2 · n 51 · Phase 2 · secondary NCT02780167
  • -14.8% vs -12.3% 30mg QD · wk 1 · n 51 · Phase 2 · secondary NCT02780167
  • -45.2% vs -35.9% 10mg QD · wk 16 · n 49 · Phase 2 · secondary NCT02780167
  • -31.5% vs -35.5% 10mg QD · wk 14 · n 49 · Phase 2 · secondary NCT02780167
  • -34.1% vs -29.8% 10mg QD · wk 13 · n 49 · Phase 2 · secondary NCT02780167
  • -31.1% vs -35.2% 10mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02780167
  • -39.4% vs -36.7% 10mg QD · wk 8 · n 49 · Phase 2 · secondary NCT02780167
  • -35.2% vs -39.2% 10mg QD · wk 6 · n 49 · Phase 2 · secondary NCT02780167
  • -30.1% vs -24.6% 10mg QD · wk 4 · n 49 · Phase 2 · secondary NCT02780167
  • -14.8% vs -23.5% 10mg QD · wk 2 · n 49 · Phase 2 · secondary NCT02780167
  • -13.8% vs -12.3% 10mg QD · wk 1 · n 49 · Phase 2 · secondary NCT02780167
upadacitinib
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. abrocitinib: 15 of 15 rows · upadacitinib: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricabrocitinib
Rows use multiple source trials
upadacitinib
Rows use multiple source trials
BSA
absolute change · percentage points
-80.6% (n=362) vs -73.7% (n=365) Dupilumab @ 16wk200 mg QDa,b,c
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
8 other source trials
-32.9% (n=238) vs -19.6% (n=131) placebo @ 16wk100 mg
NCT03720470 · Phase 3
-39% (n=226) vs -19.6% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
-90.9% (n=264) vs -68.5% (n=266) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-96.3% (n=265) vs -68.5% (n=266) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-5.55% (n=56) vs -8.09% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-14.64% (n=49) vs -8.09% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.88% (n=55) vs -8.09% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.52% (n=51) vs -8.09% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-27.1% (n=42) vs -4.1% (n=39) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
-30.7% (n=42) vs -4.1% (n=39) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-11.7% (n=42) vs -4.1% (n=39) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
DLQI 4-point Improvement
responder rate · % of participants
67.2% (n=117) vs 43.6% (n=56) placebo @ 12wk100 mgd,b,c,e
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 1 more dose
72.6% (n=117) vs 43.6% (n=56) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
68.2% (n=22) vs 19.2% (n=26) placebo @ 16wk15 mg QDd,b,c,e
NCT03607422 · Phase 3
show 3 more doses
71.7% (n=251) vs 28.4% (n=250) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
73.3% (n=30) vs 19.2% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
77.6% (n=251) vs 28.4% (n=250) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
EASI 100
responder rate · % of participants
12.7% (n=238) vs 4% (n=131) placebo @ 16wk100 mgd,b,c
NCT03720470 · Phase 3
show 1 more dose
13.6% (n=226) vs 4% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
15.5% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QDd,b,c
NCT03607422 · Phase 3
show 3 more doses
14.1% (n=276) vs 0.7% (n=278) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
19.4% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
18.8% (n=282) vs 0.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
EASI-50
responder rate · % of participants
81.2% (n=238) vs 57.3% (n=131) placebo @ 16wk100 mgd,a,b,c
NCT03720470 · Phase 3
show 1 more dose
87.3% (n=226) vs 57.3% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
71.4% (n=42) vs 22% (n=41) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
83.3% (n=42) vs 22% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 22% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
EASI-75
responder rate · % of participants
No placebo or comparator arm
69% (n=100) @ 12wk100 mgd,f,b,c
NCT05375929 · Phase 3 · registry result, not featured evidence
show 1 more dose
71.7% (n=99) @ 12wk200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
64.4% (n=222) @ 12wk15 mgd,f,b,c
NCT05507580 · Phase 4 · registry result, not featured evidence
show 1 more dose
79.3% (n=227) @ 12wk30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
IGA 0/1
responder rate · % of participants
55.3% (n=362) vs 42.5% (n=365) Dupilumab @ 16wk200 mg QDa,b,c
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2 other source trials
55.5% (n=264) vs 15.4% (n=267) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
77.8% (n=266) vs 15.4% (n=267) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
31% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Pruritus NRS 4-point Improvement
responder rate · % of participants
54.6% (n=254) vs 15.9% (n=258) placebo @ 16wk100 mgd,a,b,c
NCT03627767 · Phase 3 · registry result, not featured evidence
show 1 more dose
75.6% (n=250) vs 15.9% (n=258) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
59.4% (n=32) vs 5.7% (n=35) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
52.8% (n=36) vs 5.7% (n=35) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
24.3% (n=37) vs 5.7% (n=35) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
SCORAD
percent change · % of baseline
-70.6% (n=362) vs -64.4% (n=365) Dupilumab @ 16wk200 mg QDb,c
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6 other source trials
-71.7% (n=264) vs -50.4% (n=265) placebo @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-83.6% (n=265) vs -50.4% (n=265) placebo @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-29.13% (n=56) vs -31.972% (n=56) placebo @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-30.135% (n=49) vs -31.972% (n=56) placebo @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-34.995% (n=55) vs -31.972% (n=56) placebo @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-19.794% (n=51) vs -31.972% (n=56) placebo @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-57.89% (n=54) vs -27.91% (n=30) placebo @ 16wk15 mg QDd,b,c
NCT03607422 · Phase 3
show 3 more doses
-57.9% (n=245) vs -28.43% (n=136) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-72.81% (n=49) vs -27.91% (n=30) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-68.44% (n=241) vs -28.43% (n=136) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
SCORAD 50
responder rate · % of participants
56.1% (n=238) vs 33.3% (n=131) placebo @ 16wk100 mgd,a,b,c
NCT03720470 · Phase 3
show 1 more dose
68.8% (n=226) vs 33.3% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
42.9% (n=42) vs 7.3% (n=41) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
61.9% (n=42) vs 7.3% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
28.6% (n=42) vs 7.3% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
SCORAD75
responder rate · % of participants
26.8% (n=238) vs 10.6% (n=131) placebo @ 16wk100 mgd,a,b,c
NCT03720470 · Phase 3
show 1 more dose
40.3% (n=226) vs 10.6% (n=131) placebo @ 16wk200 mg
NCT03720470 · Phase 3
21.4% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mgd,a,b,c
NCT02925117 · Phase 2 · registry result, not featured evidence
show 2 more doses
40.5% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Time to Loss of Response
time to event · months
2.56 vs 0.89 placebo months*100 mgd,a,b,c,g
NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 78 days as posted
show 3 more doses
10.61 vs 0.92 placebo months*100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 323 days as posted
6.6 vs 0.89 placebo months*200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence · converted to months from 201 days as posted
NA vs 0.92 placebo months200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.99 vs NA placebo months*15 mgd,a,b,c,g
NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 30 days as posted
show 6 more doses
3.75 vs NA placebo months*15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 114 days as posted
NA vs NA placebo months30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0.92 vs NA placebo months*30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 28 days as posted
NA vs NA placebo months30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0.95 vs NA placebo months*7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence · converted to months from 29 days as posted
NA vs NA placebo months7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Dropout rate
13.5%100 mgh
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
11%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.7%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.3%100 mg
NCT03575871 · Phase 3
9%200 mg
NCT03575871 · Phase 3
—100 mg
NCT03720470 · Phase 3
8.8%100 mg
NCT03720470 · Phase 3
—200 mg
NCT03720470 · Phase 3
8%200 mg
NCT03720470 · Phase 3
3.2%100mg QD
NCT03796676 · Phase 3
3.2%200mg QD
NCT03796676 · Phase 3
6.9%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
8.1%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
35.4%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
12.5%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
7.1%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
33.9%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
30.9%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
47.1%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
44.9%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
—15 mgi
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
5.2%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
4.1%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
3.2%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
4.5%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
3.3%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
4.9%30 mg QD
NCT03569293 · Phase 3
5.2%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
2.6%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
10.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
16.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
8.8%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.9%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
5.8%100 mgh
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
5.8%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%100 mg
NCT03575871 · Phase 3
3.2%200 mg
NCT03575871 · Phase 3
—100 mg
NCT03720470 · Phase 3
2.5%100 mg
NCT03720470 · Phase 3
—200 mg
NCT03720470 · Phase 3
4%200 mg
NCT03720470 · Phase 3
1.1%100mg QD
NCT03796676 · Phase 3
2.1%200mg QD
NCT03796676 · Phase 3
0%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
1%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
—200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
—100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
4%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
12.5%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
7.1%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
21.4%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
14.5%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
15.7%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
16.3%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
—15 mgi
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0.4%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
0.4%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
1.6%30 mg QD
NCT03569293 · Phase 3
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
2%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Serious AEs
3.2%100 mgh
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
3.2%200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.7%200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
3.2%100 mg
NCT03575871 · Phase 3
1.3%200 mg
NCT03575871 · Phase 3
2.5%100 mg
NCT03720470 · Phase 3
0.5%100 mg
NCT03720470 · Phase 3
0.9%200 mg
NCT03720470 · Phase 3
0%200 mg
NCT03720470 · Phase 3
0%100mg QD
NCT03796676 · Phase 3
1.1%200mg QD
NCT03796676 · Phase 3
1%100 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
0%100 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
0%200 mg QD
NCT05375929 · Phase 3 · registry result, not featured evidence
0%200 mg
NCT05375929 · Phase 3 · registry result, not featured evidence
3.4%100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.6%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
5.3%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.1%200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0%100 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
0%200 mg QD
NCT03915496 · Phase 2 · registry result, not featured evidence
5.4%100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
3.6%200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
0%30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
4.1%10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
15.4%15 mgi
NCT03607422 · Phase 3
show 48 more results
10.9%15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
10.6%15 mg
NCT03607422 · Phase 3
16.6%15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
13.8%30 mg
NCT03607422 · Phase 3
16.9%30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
17.3%30 mg
NCT03607422 · Phase 3
17.4%30 mg
NCT03607422 · Phase 3
2.8%30 mg QD
NCT03607422 · Phase 3
3.3%15 mg
NCT03569293 · Phase 3
12.5%15 mg QD
NCT03569293 · Phase 3
3.1%15 mg QD
NCT03569293 · Phase 3
14.7%15 mg
NCT03569293 · Phase 3
14.3%15 mg
NCT03569293 · Phase 3
2.1%15 mg QD
NCT03569293 · Phase 3
22.2%30 mg
NCT03569293 · Phase 3
10.9%30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
20%30 mg
NCT03569293 · Phase 3
18.4%30 mg
NCT03569293 · Phase 3
3.3%30 mg QD
NCT03569293 · Phase 3
3.5%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.4%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.7%15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.8%30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
5.9%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
5.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.1%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
6.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
100 mgh
nasopharyngitis 14.7% (placebo 10.4%)
dermatitis atopic 14.1% (placebo 16.9%)
nausea 9% (placebo 2.6%)
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 24 more results
200 mg
nausea 20.1% (placebo 2.6%)
nasopharyngitis 11.7% (placebo 10.4%)
headache 9.7% (placebo 2.6%)
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
200 mg QD
nausea 19.3%
headache 13%
acne 12.7%
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
100 mg
nasopharyngitis 12.7% (placebo 6.4%)
upper respiratory tract infection 8.9% (placebo 3.8%)
nausea 7.6% (placebo 2.6%)
NCT03575871 · Phase 3
200 mg
nausea 14.2% (placebo 2.6%)
headache 7.7% (placebo 2.6%)
nasopharyngitis 7.7% (placebo 6.4%)
NCT03575871 · Phase 3
100 mg
nasopharyngitis 9.2% (placebo 6.9%)
upper respiratory tract infection 5% (placebo 4.6%)
headache 4.2% (placebo 4.6%)
NCT03720470 · Phase 3
100 mg
upper respiratory tract infection 2.8% (placebo 4.6%)
cough 1.4% (placebo 1.5%)
diarrhoea 1.4% (placebo 3.1%)
NCT03720470 · Phase 3
200 mg
nausea 11.1% (placebo 1.5%)
acne 6.6% (placebo 0%)
headache 6.6% (placebo 4.6%)
NCT03720470 · Phase 3
200 mg
nasopharyngitis 4.3% (placebo 6.9%)
upper respiratory tract infection 2.4% (placebo 4.6%)
dermatitis atopic 1.9% (placebo 3.1%)
NCT03720470 · Phase 3
100mg QD
upper respiratory tract infection 9.5% (placebo 10.4%)
nasopharyngitis 8.4% (placebo 9.4%)
folliculitis 7.4% (placebo 1%)
NCT03796676 · Phase 3
200mg QD
nausea 18.1% (placebo 1%)
upper respiratory tract infection 10.6% (placebo 10.4%)
headache 8.5% (placebo 7.3%)
NCT03796676 · Phase 3
100 mg QD
nausea 5%
dermatitis atopic 4%
alanine aminotransferase increased 3%
NCT05375929 · Phase 3 · registry result, not featured evidence
100 mg
nasopharyngitis 10.5%
nausea 10.5%
cough 5.3%
NCT05375929 · Phase 3 · registry result, not featured evidence
200 mg QD
nausea 9.1%
gastrooesophageal reflux disease 4%
pruritus 4%
NCT05375929 · Phase 3 · registry result, not featured evidence
200 mg
dermatitis atopic 12.5%
pyrexia 12.5%
asthma 6.3%
NCT05375929 · Phase 3 · registry result, not featured evidence
100 mg
dermatitis atopic 21.1% (placebo 33%)
nausea 13.2% (placebo 16.5%)
nasopharyngitis 10.2% (placebo 9.7%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
nausea 16.1% (placebo 16.5%)
headache 9.7% (placebo 11.6%)
nasopharyngitis 6.2% (placebo 9.7%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
nausea 18.4% (placebo 16.5%)
dermatitis atopic 13.5% (placebo 33%)
acne 11.7% (placebo 7.1%)
NCT03627767 · Phase 3 · registry result, not featured evidence
200 mg
upper respiratory tract infection 6% (placebo 9.7%)
nasopharyngitis 4.8% (placebo 9.7%)
dermatitis atopic 3.7% (placebo 33%)
NCT03627767 · Phase 3 · registry result, not featured evidence
100 mg QD
nausea 18.8% (placebo 6.3%)
dizziness 12.5% (placebo 0%)
abdominal discomfort 6.3% (placebo 0%)
NCT03915496 · Phase 2 · registry result, not featured evidence
200 mg QD
nausea 28.6% (placebo 6.3%)
headache 14.3% (placebo 0%)
abdominal distension 7.1% (placebo 0%)
NCT03915496 · Phase 2 · registry result, not featured evidence
100mg QD
viral upper respiratory tract infection 17.9% (placebo 8.9%)
dermatitis atopic 12.5% (placebo 10.7%)
headache 8.9% (placebo 3.6%)
NCT02780167 · Phase 2 · registry result, not featured evidence
200mg QD
nausea 14.5% (placebo 1.8%)
dermatitis atopic 12.7% (placebo 10.7%)
viral upper respiratory tract infection 12.7% (placebo 8.9%)
NCT02780167 · Phase 2 · registry result, not featured evidence
30mg QD
dermatitis atopic 17.6% (placebo 10.7%)
viral upper respiratory tract infection 11.8% (placebo 8.9%)
headache 9.8% (placebo 3.6%)
NCT02780167 · Phase 2 · registry result, not featured evidence
10mg QD
dermatitis atopic 16.3% (placebo 10.7%)
viral upper respiratory tract infection 10.2% (placebo 8.9%)
diarrhoea 6.1% (placebo 1.8%)
NCT02780167 · Phase 2 · registry result, not featured evidence
15 mgi
covid-19 23.1% (placebo 0%)
acne 19.2% (placebo 3.3%)
dermatitis atopic 19.2% (placebo 13.3%)
NCT03607422 · Phase 3
show 38 more results
15 mg
covid-19 27.3% (placebo 0%)
upper respiratory tract infection 21.8% (placebo 1.7%)
acne 18.2% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg QD
acne 10.3% (placebo 3.3%)
upper respiratory tract infection 10.3% (placebo 1.7%)
oropharyngeal pain 6.9% (placebo 0%)
NCT03607422 · Phase 3
15 mg
covid-19 31.7% (placebo 0%)
acne 19.2% (placebo 3.3%)
blood creatine phosphokinase increased 17.3% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg
covid-19 31.9% (placebo 0%)
dermatitis atopic 17.9% (placebo 13.3%)
upper respiratory tract infection 14.4% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg QD
acne 12.8% (placebo 3.3%)
headache 7% (placebo 3.3%)
nasopharyngitis 6.2% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 41.4% (placebo 0%)
acne 34.5% (placebo 3.3%)
dermatitis atopic 24.1% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 32.2% (placebo 0%)
blood creatine phosphokinase increased 18.6% (placebo 1.7%)
acne 11.9% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg QD
acne 14.5% (placebo 3.3%)
blood creatine phosphokinase increased 9.7% (placebo 1.7%)
headache 8.1% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 39.4% (placebo 0%)
acne 25% (placebo 3.3%)
dermatitis atopic 15.4% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 29.8% (placebo 0%)
blood creatine phosphokinase increased 18.3% (placebo 1.7%)
dermatitis atopic 14.9% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg QD
acne 15% (placebo 3.3%)
nasopharyngitis 8.1% (placebo 3.3%)
headache 6.5% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg
covid-19 20% (placebo 0%)
acne 16.7% (placebo 1.6%)
blood creatine phosphokinase increased 16.7% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
covid-19 25% (placebo 0%)
upper respiratory tract infection 21.9% (placebo 8.2%)
blood creatine phosphokinase increased 12.5% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
acne 14.1% (placebo 1.6%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
headache 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg
covid-19 38.2% (placebo 0%)
dermatitis atopic 18.6% (placebo 3.3%)
upper respiratory tract infection 18.6% (placebo 8.2%)
NCT03569293 · Phase 3
15 mg
covid-19 28.6% (placebo 0%)
nasopharyngitis 16.5% (placebo 1.6%)
dermatitis atopic 16% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
upper respiratory tract infection 9.6% (placebo 8.2%)
nasopharyngitis 7.9% (placebo 1.6%)
acne 5.4% (placebo 1.6%)
NCT03569293 · Phase 3
30 mg
acne 37% (placebo 1.6%)
upper respiratory tract infection 33.3% (placebo 8.2%)
dermatitis atopic 29.6% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
covid-19 35.9% (placebo 0%)
acne 28.1% (placebo 1.6%)
upper respiratory tract infection 28.1% (placebo 8.2%)
NCT03569293 · Phase 3
30 mg QD
acne 15.6% (placebo 1.6%)
upper respiratory tract infection 12.5% (placebo 8.2%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 38.1% (placebo 0%)
acne 22.9% (placebo 1.6%)
blood creatine phosphokinase increased 17.1% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 35.1% (placebo 0%)
acne 18.9% (placebo 1.6%)
dermatitis atopic 18% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
acne 16.5% (placebo 1.6%)
upper respiratory tract infection 12.8% (placebo 8.2%)
nasopharyngitis 11.5% (placebo 1.6%)
NCT03569293 · Phase 3
15 mg
acne 7%
nasopharyngitis 5.7%
upper respiratory tract infection 3.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg
nasopharyngitis 11.1%
dermatitis atopic 8.3%
upper respiratory tract infection 6.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg then 30 mg
dermatitis atopic 16%
nasopharyngitis 4.2%
acne 2.8%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 13.8%
nasopharyngitis 9.1%
dermatitis atopic 3.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg then 15 mg
dermatitis atopic 12%
nasopharyngitis 7.5%
acne 6%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
dermatitis atopic 16.5%
acne 6.6%
eczema 5.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 20.5%
covid-19 13.4%
blood creatine phosphokinase increased 13%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg
acne 22.9%
dermatitis atopic 19.1%
blood creatine phosphokinase increased 14.8%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg QD
acne 18.7%
dermatitis atopic 10.5%
blood creatine phosphokinase increased 7.6%
NCT03738397 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
nasopharyngitis 11.9% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 11.9% (placebo 5.4%)
nasopharyngitis 9.5% (placebo 1.1%)
blood creatine phosphokinase increased 7.1% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 22.8% (placebo 5.4%)
dermatitis atopic 19.3% (placebo 2.2%)
acne 11.4% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
acne 14.3% (placebo 1.1%)
upper respiratory tract infection 11.9% (placebo 5.4%)
blood creatine phosphokinase increased 9.5% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 14.3% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. eAssessment timepoints differ: 16 weeks versus 12 weeks.
  6. fTrial phases differ: Phase 4 versus Phase 3.
  7. gThe assessment timepoint is not available for both results.
  8. hPopulation comparability has not been reviewed for 22 of these studies.
  9. iPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

abrocitinib

PSAAD -1.5 vs -0.5 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 55 more results
-1.8 vs -0.7 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.2 vs -1.2 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.2 vs -1.1 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -1.1 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.4 vs -0.8 placebo score @ 12wk100 mg
NCT03575871 · Phase 3
-1.1 vs -0.5 placebo score @ 1wk100 mg
NCT03720470 · Phase 3
-1.8 vs -0.9 placebo score @ 2wk100 mg
NCT03720470 · Phase 3
-2.2 vs -1.1 placebo score @ 3wk100 mg
NCT03720470 · Phase 3
-2.4 vs -1.4 placebo score @ 4wk100 mg
NCT03720470 · Phase 3
-2.6 vs -1.5 placebo score @ 5wk100 mg
NCT03720470 · Phase 3
-2.6 vs -1.5 placebo score @ 6wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 7wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.5 placebo score @ 8wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.7 placebo score @ 9wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.7 placebo score @ 10wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 11wk100 mg
NCT03720470 · Phase 3
-2.7 vs -1.6 placebo score @ 12wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.7 placebo score @ 13wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.6 placebo score @ 14wk100 mg
NCT03720470 · Phase 3
-2.9 vs -1.7 placebo score @ 15wk100 mg
NCT03720470 · Phase 3
-2.8 vs -1.7 placebo score @ 16wk100 mg
NCT03720470 · Phase 3
-2.5 vs -2 placebo score @ 12wk100mg QD
NCT03796676 · Phase 3
-4.2 vs -4.1 placebo score @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.8 vs 2.1 placebo score @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1 vs 2.3 placebo score @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1 vs 2 placebo score @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.2 vs 1.9 placebo score @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-2.1 vs -0.5 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3 vs -0.7 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.1 vs -1.2 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.2 vs -1.1 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.4 vs -1.1 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3 vs -0.8 placebo score @ 12wk200 mg
NCT03575871 · Phase 3
-1.3 vs -0.5 placebo score @ 1wk200 mg
NCT03720470 · Phase 3
-2.3 vs -0.9 placebo score @ 2wk200 mg
NCT03720470 · Phase 3
-2.8 vs -1.1 placebo score @ 3wk200 mg
NCT03720470 · Phase 3
-3 vs -1.4 placebo score @ 4wk200 mg
NCT03720470 · Phase 3
-3.2 vs -1.5 placebo score @ 5wk200 mg
NCT03720470 · Phase 3
-3.3 vs -1.5 placebo score @ 6wk200 mg
NCT03720470 · Phase 3
-3.4 vs -1.6 placebo score @ 7wk200 mg
NCT03720470 · Phase 3
-3.4 vs -1.5 placebo score @ 8wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.7 placebo score @ 9wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.7 placebo score @ 10wk200 mg
NCT03720470 · Phase 3
-3.5 vs -1.6 placebo score @ 11wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.6 placebo score @ 12wk200 mg
NCT03720470 · Phase 3
-3.7 vs -1.7 placebo score @ 13wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.6 placebo score @ 14wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.7 placebo score @ 15wk200 mg
NCT03720470 · Phase 3
-3.6 vs -1.7 placebo score @ 16wk200 mg
NCT03720470 · Phase 3
-2.7 vs -2 placebo score @ 12wk200mg QD
NCT03796676 · Phase 3
-4.2 vs -4.1 placebo score @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.1 vs 2.1 placebo score @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.1 vs 2.3 placebo score @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.3 vs 2 placebo score @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.2 vs 1.9 placebo score @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
Time to Response 2.76 vs 3.02 placebo months100 mg
time to event · months
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 84 days as posted
show 2 more results
0.46 vs 3.02 placebo months*200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 14 days as posted
0.36 vs 0.82 Dupilumab months*200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3 · converted to months from 11 days as posted
IGA 0 0% (n=156) vs 0% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 15 more results
0% (n=156) vs 0% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
4.6% (n=156) vs 0% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
7.1% (n=156) vs 0% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
1.9% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
1.3% (n=158) vs 0% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
5.2% (n=158) vs 0% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
0% (n=154) vs 0% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
6.6% (n=154) vs 0% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
11.7% (n=154) vs 0% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
13.1% (n=154) vs 0% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
2% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
4.6% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
4.5% (n=155) vs 0% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
6.5% (n=155) vs 0% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
EASI -9.8 vs -4.1 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 7 more results
-14.7 vs -6.8 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-16.3 vs -7.8 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-16.6 vs -8.2 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-14.7 vs -4.1 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-19.6 vs -6.8 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-21.3 vs -7.8 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-22.3 vs -8.2 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
BSA Less Than 5 2.6% (n=156) vs 1.3% (n=77) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 17 more results
8.6% (n=156) vs 3.9% (n=77) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
16.2% (n=156) vs 6.7% (n=77) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
21.2% (n=156) vs 5.3% (n=77) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
1.9% (n=158) vs 0% (n=78) placebo @ 2wk100 mg
NCT03575871 · Phase 3
6.5% (n=158) vs 0% (n=78) placebo @ 4wk100 mg
NCT03575871 · Phase 3
15.9% (n=158) vs 1.3% (n=78) placebo @ 8wk100 mg
NCT03575871 · Phase 3
22.6% (n=158) vs 3.9% (n=78) placebo @ 12wk100 mg
NCT03575871 · Phase 3
38.2% (n=89) vs 24.5% (n=94) placebo @ 12wk100mg QD
NCT03796676 · Phase 3
5.2% (n=154) vs 1.3% (n=77) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
27.6% (n=154) vs 3.9% (n=77) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
33.1% (n=154) vs 6.7% (n=77) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
38.6% (n=154) vs 5.3% (n=77) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
5.9% (n=155) vs 0% (n=78) placebo @ 2wk200 mg
NCT03575871 · Phase 3
17% (n=155) vs 0% (n=78) placebo @ 4wk200 mg
NCT03575871 · Phase 3
27.3% (n=155) vs 1.3% (n=78) placebo @ 8wk200 mg
NCT03575871 · Phase 3
34.4% (n=155) vs 3.9% (n=78) placebo @ 12wk200 mg
NCT03575871 · Phase 3
36.6% (n=93) vs 24.5% (n=94) placebo @ 12wk200mg QD
NCT03796676 · Phase 3
SCORAD Sleep Loss -2.1 vs -0.8 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 23 more results
-2.5 vs -1 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.8 vs -1.3 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.9 vs -1.6 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-1.9 vs -0.5 placebo score @ 2wk100 mg
NCT03575871 · Phase 3
-2.8 vs -1 placebo score @ 4wk100 mg
NCT03575871 · Phase 3
-3.1 vs -1.5 placebo score @ 8wk100 mg
NCT03575871 · Phase 3
-3 vs -2.1 placebo score @ 12wk100 mg
NCT03575871 · Phase 3
-2.1 vs -0.9 placebo score @ 2wk100mg QD
NCT03796676 · Phase 3
-2.9 vs -1.8 placebo score @ 4wk100mg QD
NCT03796676 · Phase 3
-3.3 vs -2.2 placebo score @ 8wk100mg QD
NCT03796676 · Phase 3
-3.5 vs -2.7 placebo score @ 12wk100mg QD
NCT03796676 · Phase 3
-3.1 vs -0.8 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.7 vs -1 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.8 vs -1.3 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-3.7 vs -1.6 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-2.9 vs -0.5 placebo score @ 2wk200 mg
NCT03575871 · Phase 3
-3.9 vs -1 placebo score @ 4wk200 mg
NCT03575871 · Phase 3
-3.9 vs -1.5 placebo score @ 8wk200 mg
NCT03575871 · Phase 3
-3.8 vs -2.1 placebo score @ 12wk200 mg
NCT03575871 · Phase 3
-2.6 vs -0.9 placebo score @ 2wk200mg QD
NCT03796676 · Phase 3
-3.4 vs -1.8 placebo score @ 4wk200mg QD
NCT03796676 · Phase 3
-3.7 vs -2.2 placebo score @ 8wk200mg QD
NCT03796676 · Phase 3
-3.9 vs -2.7 placebo score @ 12wk200mg QD
NCT03796676 · Phase 3
SCORAD -16.4 vs -5.5 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 51 more results
-23.1 vs -10.5 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-26 vs -11.7 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-27 vs -13.6 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-24.6 vs -12.3 placebo score @ 2wk100mg QD
NCT03796676 · Phase 3
-32.4 vs -20.2 placebo score @ 4wk100mg QD
NCT03796676 · Phase 3
-37.3 vs -26.6 placebo score @ 8wk100mg QD
NCT03796676 · Phase 3
-40.9 vs -30.2 placebo score @ 12wk100mg QD
NCT03796676 · Phase 3
-12.024 vs -7.91 placebo score @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-20.286 vs -10.905 placebo score @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-28.058 vs -14.555 placebo score @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-29.729 vs -19.527 placebo score @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-30.148 vs -19.052 placebo score @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-33.145 vs -18.647 placebo score @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-24.261 vs -16.603 placebo score @ 13wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-20.211 vs -17.987 placebo score @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.753 vs -19.408 placebo score @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-24.4 vs -5.5 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-32.6 vs -10.5 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-33.7 vs -11.7 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-35.5 vs -13.6 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-25.8 vs -12.3 placebo score @ 2wk200mg QD
NCT03796676 · Phase 3
-38 vs -20.2 placebo score @ 4wk200mg QD
NCT03796676 · Phase 3
-41.5 vs -26.6 placebo score @ 8wk200mg QD
NCT03796676 · Phase 3
-42.9 vs -30.2 placebo score @ 12wk200mg QD
NCT03796676 · Phase 3
-21.326 vs -7.91 placebo score @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-32.152 vs -10.905 placebo score @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-39.567 vs -14.555 placebo score @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-41.458 vs -19.527 placebo score @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-42.604 vs -19.052 placebo score @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-41.384 vs -18.647 placebo score @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-29.884 vs -16.603 placebo score @ 13wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-21.292 vs -17.987 placebo score @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-21.024 vs -19.408 placebo score @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-8.388 vs -7.91 placebo score @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-13.266 vs -10.905 placebo score @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-15.496 vs -14.555 placebo score @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-19.93 vs -19.527 placebo score @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-19.534 vs -19.052 placebo score @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-21.211 vs -18.647 placebo score @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-15.023 vs -16.603 placebo score @ 13wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-12.768 vs -17.987 placebo score @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-12.716 vs -19.408 placebo score @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-5 vs -7.91 placebo score @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-8.795 vs -10.905 placebo score @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-14.116 vs -14.555 placebo score @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-16.667 vs -19.527 placebo score @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-18.853 vs -19.052 placebo score @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-17.986 vs -18.647 placebo score @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-16.895 vs -16.603 placebo score @ 13wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-15.842 vs -17.987 placebo score @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-18.925 vs -19.408 placebo score @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
PSAAD 1 Point Improvement 51.1% (n=135) vs 28.4% (n=67) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 7 more results
62.7% (n=135) vs 44.8% (n=67) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
60.9% (n=135) vs 44.8% (n=67) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
61.4% (n=135) vs 40.9% (n=67) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
68.9% (n=136) vs 28.4% (n=67) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
77.3% (n=136) vs 44.8% (n=67) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
69.1% (n=136) vs 44.8% (n=67) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
70.3% (n=136) vs 40.9% (n=67) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
DLQI -5.9 vs -2.1 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 60 more results
-6.8 vs -3.5 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.8 vs -4 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7 vs -4.2 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.7 vs -4.5 placebo score @ 2wk100 mg
NCT03720470 · Phase 3
-8.7 vs -6.2 placebo score @ 12wk100 mg
NCT03720470 · Phase 3
-9 vs -6.2 placebo score @ 16wk100 mg
NCT03720470 · Phase 3
-13.4 vs -13.5 placebo score @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.9 vs 6.9 placebo score @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
2.1 vs 6.1 placebo score @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
2.5 vs 4.4 placebo score @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
2.8 vs 3.6 placebo score @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-5.1 vs -1.4 placebo score @ 1wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-7.5 vs -2.3 placebo score @ 2wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-8.2 vs -2.6 placebo score @ 4wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.1 vs -4.2 placebo score @ 6wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.2 vs -3.7 placebo score @ 8wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.8 vs -4.6 placebo score @ 12wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-6.2 vs -3.1 placebo score @ 14wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.6 vs -4.5 placebo score @ 16wk100mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-7.6 vs -2.1 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.6 vs -3.5 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.3 vs -4 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-9.1 vs -4.2 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.6 vs -6.7 Dupilumab score @ 2wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.7 vs -9.7 Dupilumab score @ 12wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.8 vs -10 Dupilumab score @ 16wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.8 vs -10.1 Dupilumab score @ 20wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-10.3 vs -10 Dupilumab score @ 26wk200 mg QD
NCT04345367 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.5 vs -4.5 placebo score @ 2wk200 mg
NCT03720470 · Phase 3
-11 vs -6.2 placebo score @ 12wk200 mg
NCT03720470 · Phase 3
-11.7 vs -6.2 placebo score @ 16wk200 mg
NCT03720470 · Phase 3
-13.5 vs -13.5 placebo score @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.4 vs 6.9 placebo score @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.9 vs 6.1 placebo score @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.1 vs 4.4 placebo score @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.9 vs 3.6 placebo score @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-6.3 vs -1.4 placebo score @ 1wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-8.6 vs -2.3 placebo score @ 2wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.7 vs -2.6 placebo score @ 4wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-10.2 vs -4.2 placebo score @ 6wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.8 vs -3.7 placebo score @ 8wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-9.5 vs -4.6 placebo score @ 12wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.4 vs -3.1 placebo score @ 14wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.6 vs -4.5 placebo score @ 16wk200mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.4 vs -1.4 placebo score @ 1wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-5 vs -2.3 placebo score @ 2wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.7 vs -2.6 placebo score @ 4wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.1 vs -4.2 placebo score @ 6wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.8 vs -3.7 placebo score @ 8wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-5.2 vs -4.6 placebo score @ 12wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.6 vs -3.1 placebo score @ 14wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.5 vs -4.5 placebo score @ 16wk30mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-1.4 vs -1.4 placebo score @ 1wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-1.9 vs -2.3 placebo score @ 2wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.7 vs -2.6 placebo score @ 4wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.6 vs -4.2 placebo score @ 6wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-5.6 vs -3.7 placebo score @ 8wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.5 vs -4.6 placebo score @ 12wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-3.9 vs -3.1 placebo score @ 14wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
-4.5 vs -4.5 placebo score @ 16wk10mg QD
NCT02780167 · Phase 2 · registry result, not featured evidence
CDLQI -4.5 vs -3.3 placebo score @ 2wk100 mg
absolute change · score
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 25 more results
-5.3 vs -1.8 placebo score @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-5.2 vs -3.1 placebo score @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.4 vs -3.9 placebo score @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.1 vs -4.2 placebo score @ 2wk100mg QD
NCT03796676 · Phase 3
-7.3 vs -5.4 placebo score @ 4wk100mg QD
NCT03796676 · Phase 3
-8.1 vs -6.1 placebo score @ 8wk100mg QD
NCT03796676 · Phase 3
-8.6 vs -6.3 placebo score @ 12wk100mg QD
NCT03796676 · Phase 3
-9.2 vs -9.8 placebo score @ 12wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.7 vs 5.9 placebo score @ 16wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.6 vs 1.5 placebo score @ 28wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.7 vs 2.1 placebo score @ 40wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
1.3 vs 2.3 placebo score @ 52wk100 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-5.8 vs -3.3 placebo score @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-8.2 vs -1.8 placebo score @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.5 vs -3.1 placebo score @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-7.5 vs -3.9 placebo score @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
-6.3 vs -4.2 placebo score @ 2wk200mg QD
NCT03796676 · Phase 3
-7.6 vs -5.4 placebo score @ 4wk200mg QD
NCT03796676 · Phase 3
-8.2 vs -6.1 placebo score @ 8wk200mg QD
NCT03796676 · Phase 3
-8.7 vs -6.3 placebo score @ 12wk200mg QD
NCT03796676 · Phase 3
-9.3 vs -9.8 placebo score @ 12wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
-0.3 vs 5.9 placebo score @ 16wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.4 vs 1.5 placebo score @ 28wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0 vs 2.1 placebo score @ 40wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
0.4 vs 2.3 placebo score @ 52wk200 mg
NCT03627767 · Phase 3 · registry result, not featured evidence
DLQI Less Than 2 10% (n=120) vs 3.4% (n=59) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 7 more results
15.3% (n=120) vs 8.5% (n=59) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
17.8% (n=120) vs 8.8% (n=59) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
20.2% (n=120) vs 12.1% (n=59) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
23.5% (n=119) vs 3.4% (n=59) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
32.5% (n=119) vs 8.5% (n=59) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
35.3% (n=119) vs 8.8% (n=59) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
31.9% (n=119) vs 12.1% (n=59) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
CDLQI Less Than 2 3.2% (n=31) vs 0% (n=16) placebo @ 2wk100 mg
responder rate · % of participants
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
show 7 more results
13.3% (n=31) vs 0% (n=16) placebo @ 4wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
12.9% (n=31) vs 7.1% (n=16) placebo @ 8wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
19.4% (n=31) vs 0% (n=16) placebo @ 12wk100 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
0% (n=31) vs 0% (n=16) placebo @ 2wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.7% (n=31) vs 0% (n=16) placebo @ 4wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
12.9% (n=31) vs 7.1% (n=16) placebo @ 8wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3
9.7% (n=31) vs 0% (n=16) placebo @ 12wk200 mg
NCT03349060 · Phase 3 · monotherapy · Atopic Dermatitis · phase 3

+ 115 further endpoints in the CSV export.

upadacitinib

vIGA-AD 0 1 38.8% (n=276) vs 4.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
44.8% (n=58) vs 5% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
48.1% (n=281) vs 8.4% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
46% (n=63) vs 6.9% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
52% (n=282) vs 4.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
59.4% (n=62) vs 5% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=285) vs 8.4% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=58) vs 6.9% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
Worst Itch NRS 4-Point Improvement 41.9% (n=270) vs 9.1% (n=274) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 38 more results
48.9% (n=270) vs 3.6% (n=274) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=270) vs 0.7% (n=274) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=269) vs 0.7% (n=267) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
11.5% (n=269) vs 3% (n=267) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
12.7% (n=55) vs 0% (n=59) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
8.9% (n=56) vs 0% (n=59) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
14.3% (n=56) vs 1.7% (n=59) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
52.2% (n=274) vs 11.8% (n=272) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
51.5% (n=274) vs 4.4% (n=272) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
15% (n=274) vs 0.4% (n=272) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
10.5% (n=275) vs 3.7% (n=270) placebo @ 0.29wk15 mg QD
NCT03569293 · Phase 3
16.4% (n=275) vs 3.3% (n=270) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 10.5% (n=57) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 3.5% (n=57) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
9.8% (n=61) vs 0% (n=57) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
16.9% (n=59) vs 5.4% (n=56) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
59.6% (n=280) vs 9.1% (n=274) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
60.7% (n=280) vs 3.6% (n=274) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
15.7% (n=280) vs 0.7% (n=274) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
7.9% (n=278) vs 0.7% (n=267) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
17.3% (n=278) vs 3% (n=267) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
56.7% (n=60) vs 3.4% (n=59) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
50% (n=60) vs 3.4% (n=59) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
5% (n=60) vs 0% (n=59) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
3.2% (n=62) vs 0% (n=59) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
9.7% (n=62) vs 1.7% (n=59) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
60% (n=280) vs 11.8% (n=272) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
66.8% (n=280) vs 4.4% (n=272) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
19.6% (n=280) vs 0.4% (n=272) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
11.8% (n=279) vs 3.7% (n=270) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
21.1% (n=279) vs 3.3% (n=270) placebo @ 0.43wk30 mg QD
NCT03569293 · Phase 3
58.9% (n=56) vs 10.5% (n=57) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
64.3% (n=56) vs 3.5% (n=57) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
23.2% (n=56) vs 0% (n=57) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
14% (n=57) vs 1.8% (n=56) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
56.1% (n=334) vs 36.4% (n=323) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
Disease Flare 2.2% (n=274) vs 24.5% (n=269) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
1.7% (n=58) vs 20% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
1.1% (n=279) vs 25.2% (n=274) placebo15 mg QD
NCT03569293 · Phase 3
0% (n=62) vs 23.2% (n=56) placebo15 mg QD
NCT03569293 · Phase 3
1.4% (n=277) vs 24.5% (n=269) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
1.6% (n=61) vs 20% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
0% (n=285) vs 25.2% (n=274) placebo30 mg QD
NCT03569293 · Phase 3
0% (n=58) vs 23.2% (n=56) placebo30 mg QD
NCT03569293 · Phase 3
WI-NRS -51.2% (n=224) vs -17.04% (n=119) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 7 more results
-47.56% (n=49) vs -11.02% (n=27) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-62.79% (n=225) vs -26.06% (n=123) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-59.01% (n=49) vs -24.36% (n=31) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-66.49% (n=235) vs -17.04% (n=119) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-66.95% (n=55) vs -11.02% (n=27) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.04% (n=236) vs -26.06% (n=123) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-70% (n=51) vs -24.36% (n=31) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
POEM 4-Point Improvement 70.9% (n=268) vs 28.7% (n=268) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
66.1% (n=56) vs 28.1% (n=57) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75% (n=278) vs 22.8% (n=276) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
80.6% (n=62) vs 27.3% (n=55) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
83.5% (n=269) vs 28.7% (n=268) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
80.7% (n=57) vs 28.1% (n=57) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
81.4% (n=280) vs 22.8% (n=276) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
87.9% (n=58) vs 27.3% (n=55) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
DLQI 0/1 23.8% (n=252) vs 4.7% (n=257) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
13.6% (n=22) vs 7.7% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
30.3% (n=258) vs 4.4% (n=252) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
22.2% (n=27) vs 4.8% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
37.9% (n=256) vs 4.7% (n=257) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
46.9% (n=32) vs 7.7% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
41.5% (n=261) vs 4.4% (n=252) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
30% (n=30) vs 4.8% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-IS Sleep Domain 12 Point Improvement 55% (n=218) vs 13.2% (n=220) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
47.9% (n=48) vs 13.3% (n=45) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
66.1% (n=218) vs 13.2% (n=220) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=41) vs 13.3% (n=45) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-SS Skin Pain 4-Point Improvement 53.6% (n=237) vs 15% (n=233) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
43.4% (n=53) vs 9.8% (n=41) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
63.5% (n=249) vs 15% (n=233) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
67.9% (n=53) vs 9.8% (n=41) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-SS TSS-7 28 Point Improvement 53.6% (n=233) vs 15% (n=226) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
51% (n=51) vs 13% (n=46) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
67.9% (n=246) vs 15% (n=226) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70% (n=50) vs 13% (n=46) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-IS Emotional State 11-point Improvement 62.6% (n=227) vs 19.8% (n=212) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
60.9% (n=46) vs 20.9% (n=43) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
72.6% (n=226) vs 19.8% (n=212) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
78.6% (n=42) vs 20.9% (n=43) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
ADerm-IS Daily Activities 14 Point Improvement 65% (n=203) vs 20.3% (n=197) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
57.1% (n=42) vs 27.5% (n=40) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
73.2% (n=205) vs 20.3% (n=197) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
81.6% (n=38) vs 27.5% (n=40) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
HADS-A D Less Than 8 45.5% (n=145) vs 14.3% (n=126) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03569293 · Phase 3
show 3 more results
48.6% (n=35) vs 3.8% (n=26) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=144) vs 14.3% (n=126) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
55.6% (n=27) vs 3.8% (n=26) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3

+ 11 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: abrocitinib's landscape · upadacitinib's landscape